Furthermore, in ONWARDS 1 and 5 trials, T2DM insulin-naïve patients were enrolled, while in ONWARDS 4 and 6 patients previously treated with basal-bolus insulin with T2DM (ONWARDS 4) and T1DM (ONWARDS 6) were enrolled. This evidence concerns the gene INS and type 2 diabetes mellitus.